PLA 2-mediated catalytic activation of its inhibitor 25-acetyl-petrosaspongiolide M: Serendipitous identification of a new PLA 2 suicide inhibitor

FEBS Letters

Volumn 578, Issue 3, 2004, Pages 269-274

  Monti, M C ^a   Casapullo, A ^a   Riccio, R ^a   Gomez Paloma, L ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

Anti inflammatory compound; Marine natural product; Mass spectrometry; Phospholipase A 2 inhibition

Indexed keywords

25 ACETYLPETROSASPONGIOLIDE M; ANTIINFLAMMATORY AGENT; PETROSASPONGIOLIDE M; PHOSPHOLIPASE A2 INHIBITOR; PRODRUG; SESTERTERPENE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; ENZYME INHIBITOR; LIGAND; OLEANOLIC ACID; PHOSPHOLIPASE A; PLA2G2A PROTEIN, HUMAN;

ARTICLE; CATALYSIS; COVALENT BOND; DEACETYLATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; ACETYLATION; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CIRCULAR DICHROISM; COMPARATIVE STUDY; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; KINETICS; MASS SPECTROMETRY; METABOLISM; MOLECULAR WEIGHT; PH; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; SPONGE (PORIFERA); TEMPERATURE;

ACETYLATION; ANIMALS; BINDING SITES; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCULAR DICHROISM; ENZYME INHIBITORS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KINETICS; LIGANDS; MASS SPECTROMETRY; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; OLEANOLIC ACID; PHOSPHOLIPASES A; PORIFERA; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TEMPERATURE;

EID: 10044279269     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2004.10.100     Document Type: Article

References (34)

1. B.C.M. Potts, D.J. Faulkner, and R.S. Jacobs Phospholipase A2 inhibitors from marine organisms J. Nat. Prod. 55 1992 1701 1717
2. 2 inactivation Mol. Pharmacol. 36 1989 782 788
3. 2 by manoalide Biochem. Pharmacol. 37 19 1988 3639 3646
4. 2 by manoalide Biochem. Pharmacol. 36 13 1987 2079 2086
5. K.B. Glaser, and R.S. Jacobs Molecular pharmacology of manoalide Biochem. Pharmacol. 35 3 1986 449 453
6. 2 by the marine natural product, manoalide Biochem. Pharmacol. 39 10 1990 1557 1564
7. A. Soriente, M. De Rosa, A. Scettri, G. Sodano, M.C. Terencio, M. Payá, and M.J. Alcaraz Manoalide Curr. Med. Chem. 6 5 1999 415 431
8. 2 inhibitors from the new Caledonian marine sponge Petrosaspongia Nigra J. Nat. Prod. 61 1998 571 575
9. 2 inhibition by Petrosaspongiolide M Chem. Bio. Chem. 3 2003 664 671
10. 2 inhibition by γ- hydroxybutenolide-containing natural products: a comparative study on petrosaspongiolides M-R Bioorganic Med. Chem. 12 6 2004 1467 2147
11. P. Vadas, and W. Pruzanski Biology of disease Laboratory Investigation 4 1986 391 404
12. 2 Nat. Struct. Biol. 2 1995 458 465
13. L. Parente Pros and Cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? J. Rheumatol. 2811 2001 2375 2382
14. 2 Annu. Rev. Pharmacol. Toxicol. 39 1999 175 189
15. M. Lehr Structure-activity relationships of (4-acylpyrrol-2-yl) alkanoic acids as inhibitors of the cytosolic phospholipase A2: variation of the substituents in positions 1, 3, and 5 J. Med. Chem. 10 1997 3381 3392
16. K.A. Hansford, R.C. Ried, C.I. Clark, J.D.A. Tyndall, M.W. Whitehouse, T. Guthrie, R.P. McGeary, K. Schafer, J.L. Martin, and D.P. Fairlie D-Tyrosine as a chiral precursor to potent inhibitors of human non pancreatic secretory phospholipase A2 (IIa) with anti-inflammatory activity Chem. Bio. Chem. 4 2003 181 185
17. 2 J. Med. Chem. 45 2002 2891 2893
18. 2 based on a 1,3-disubstituted propan-2-one skeleton J. Med. Chem. 45 2002 1348 1362
19. 2 J. Med. Chem. 43 2000 1041 1044
20. 2 inhibitor on acute and chronic inflammation J. Pharmacol. Exp. Ther. 289 1999 166 167
21. L. Posadas, M.C. Terencio, A. Randazzo, L. Gomez-Paloma, M. Payá, and M.J. Alcaraz Inhibition of the NF-kB signaling pathway mediates the anti-inflammatory effects of petrosaspongiolide M Biochem. Pharmacol. 65 2003 887 895
22. 2 and other lipases that release long-chain fatty acids Biochem. J. 226 1990 435 439
23. 2 activity using fluorescence probe ADIFAB Anal. Biochem. 229 1995 256 263
24. 2 Biochimica et Biophysica Acta 1391 1998 367 376
25. 2 from pancreas and venom using a continuous fluorescence displacement assay Biochem. J. 278 1991 843 848
26. S.M. Kelly, and N.C. Price The application of circular dichroism to studies of protein folding and unfolding Biochimica et Biophysica Acta 1338 1997 161 185
27. N. Greenfield Methods to estimate the conformation of proteins and polypeptides from circular dichroism data Anal. Biochem. 235 1996 1 10
28. E. Bianchi, S. Orru, F. Dal Piaz, R. Ingenfto, A. Casbarra, G. Biasol, U. Koch, P. Pucci, and A. Pessi Conformational changes in human hepatitis C virus NS3 protease upon binding of product-based inhibitors Biochemistry 38 1999 13844 13852
29. K. Boren, P. Andersson, M. Larsson, and U. Carlsson Characterization of a molten globule state of bovine carbonic anhydrase HI: loss of asymmetrical environment of the aromatic residues has a profound effect on both the near- and far-UV CD spectrum Biochim. Biophys. Acta 10 1999 111 118
30. D. Krzyzanowska, M. Lisowski, and M. Kochman UV-difference and CD spectroscopy studies on juvenile hormone binding to its carrier protein J. Pept. Res. 512 1998 96 102
31. J. Reed, and V. Kinzel Near- and far-ultraviolet circular dichroism of the catalytic subunit of adenosine cyclic 5′-rnonophosphate dependent protein kinase Biochemistry 23 1984 1357 1362
32. K. Ajtai, and S.Yu. Venyaminov CD study of the actin DNase I complex FEBS Lett. 151 1983 94 96
33. F. Zsila, Z. Bikadi, and M. Simonyi Induced circular dichroism spectra reveal binding of the anti-inflammatory curcumin to human alphal-acid glycoprotein Bioorg. Med. Chem. 12 2004 3239 3245
34. 2 by the marine natural products manoalide, luffariellolide and scalaradial J. Am. Chem. Soc. 114 1992 5093 5100